Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of treatment outcomes for primary tonsillar lymphoma

  • Lee, Yun Hee (Department of Radiation Oncology, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine) ;
  • Cho, Seok Goo (Department of Hematology, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Jung, Seung Eun (Department of Radiology, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Sung Hoon (Department of Nuclear Medicine, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • O, Joo Hyun (Department of Nuclear Medicine, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Park, Gyeong Sin (Department of Pathology, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Yang, Suk Woo (Department of Ophthalmology, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, In Seok (Department of Internal Medicine, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Rhee, Chin Kook (Department of Internal Medicine, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Choi, Byung Ock (Department of Radiation Oncology, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2016.05.03
  • Accepted : 2016.08.22
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Although each Waldeyer's ring sub-site is considered an independent prognostic factor, few studies have assessed the prognosis and treatment of tonsillar lymphoma. Treatment outcomes were analyzed in patients with primary tonsillar lymphoma who were treated with chemotherapy and radiotherapy (RT). Materials and Methods: Nineteen patients with diffuse large B-cell lymphoma were evaluated, with a median follow-up of 53 months. Age, sex, and histology, amongst other factors, were reviewed. Progression-free survival (PFS) and overall survival (OS) rates were analyzed. Results: Most patients had Ann Arbor stage I-II (94.7%), IPI score of 0 (89.5%), and complete remission after chemotherapy (89.5%). The 5-year PFS and OS rates were 74.6% and 80%, respectively. In univariate analysis, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen resulted in a better PFS than the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (88.9% vs. 50.0%; p = 0.053). RT dose was related to the survival outcome (p = 0.010 for PFS, p = 0.044 for OS). Patients were classified into the CHOP + RT (>40 Gy) group and R-CHOP + RT (${\leq}40Gy$) group. The 5-year PFS rates were 50% in the CHOP + RT group, and 100 % in the R-CHOP + RT group (p = 0.018). The 5-year OS rates were 66.7% and 100%, respectively (p = 0.087). Conclusion: Primary tonsillar lymphoma patients typically have favorable outcomes. Chemotherapy (R-CHOP) combined with relatively lower dose consolidative RT may be safe and effective for primary tonsillar lymphoma.

Keywords

References

  1. Lee SJ, Suh CW, Lee SI, et al. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. Korean J Intern Med 2014;29:352-60. https://doi.org/10.3904/kjim.2014.29.3.352
  2. Qin Y, Shi YK, He XH, et al. Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil. Ai Zheng 2006;25:481-5.
  3. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804. https://doi.org/10.1200/JCO.2005.07.155
  4. Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015;92:11-31. https://doi.org/10.1016/j.ijrobp.2015.01.009
  5. Chang DT, Mendenhall NP, Lynch JW, Morris CG, Olivier KR. Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring. Am J Clin Oncol 2009;32:233-7. https://doi.org/10.1097/COC.0b013e318187ddbb
  6. Mian M, Ferreri AJ, Rossi A, et al. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. Leuk Lymphoma 2013;54:62-8. https://doi.org/10.3109/10428194.2012.710907
  7. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6. https://doi.org/10.1056/NEJM199807023390104
  8. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-8. https://doi.org/10.1200/jco.2004.22.14_suppl.3032
  9. dos Santos LV, Lima JP, Lima CS, Sasse EC, Sasse AD. Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis. BMC Cancer 2012;12:288. https://doi.org/10.1186/1471-2407-12-288
  10. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:787-92. https://doi.org/10.1200/JCO.2006.07.0722
  11. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258-63. https://doi.org/10.1200/JCO.2007.13.6929
  12. Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170-6. https://doi.org/10.1200/JCO.2009.27.3441
  13. Laskar S, Bahl G, Muckaden MA, et al. Primary diffuse large B-cell lymphoma of the tonsil. Is a higher radiotherapy dose required? Cancer 2007;110:816-23. https://doi.org/10.1002/cncr.22841
  14. Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N. Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol 2005;84:223-6. https://doi.org/10.1007/s00277-004-0860-0
  15. Mohammadianpanah M, Daneshbod Y, Ramzi M, et al. Primary tonsillar lymphomas according to the new World Health Organization classification: to report 87 cases and literature review and analysis. Ann Hematol 2010;89:993-1001. https://doi.org/10.1007/s00277-010-0970-9
  16. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42. https://doi.org/10.1056/NEJMoa011795
  17. Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011;100:86-92. https://doi.org/10.1016/j.radonc.2011.05.013

Cited by

  1. Treatment outcome of diffuse large B-cell lymphoma involving the head and neck : Two-institutional study for the significance of radiotherapy after R-CHOP chemotherapy vol.96, pp.25, 2016, https://doi.org/10.1097/md.0000000000007268
  2. Non-Hodgkin’s lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint vol.11, pp.9, 2016, https://doi.org/10.1080/17474086.2018.1506326
  3. Development of a semi-customized tongue displacement device using a 3D printer for head and neck IMRT vol.14, pp.None, 2016, https://doi.org/10.1186/s13014-019-1289-x